Background
Methods
Study Population and Blood Collection
Clinical Information
Biomarker Assays
Statistical Analysis
Results
Patient Demographics
Total (n = 58) | FEV1% predicted ≥ median (n = 29) | FEV1% predicted < median (n = 29) |
P-value | |
---|---|---|---|---|
Age, years range | 18 - 61 | 18 - 49 | 19 - 61 | < 0.01 |
Sex, male n (%) | 34 (58.62) | 18 (62.1) | 16 (55.2) | 0.79 |
BMI, kg/m2 ± SD | 23.24 ± 3.25 | 24.2 ± 3.4 | 22.3 ± 2.9 | 0.02 |
FEV1, % predicted ± SD | 71.93 ± 24.80 | 92.9 ± 12.9 | 51.0 ± 13.2 | - |
Current medications | ||||
Azithromycin, n (%) | 18 (31.03) | 3 (10.3) | 15 (51.7) | < 0.01 |
Ciprofloxacin, n (%) | 2 (3.45) | 1 (3.4) | 1 (3.4) | 1.00 |
Dornase alfa, n (%) | 24 (41.38) | 11 (37.9) | 13 (44.8) | 0.79 |
Ibuprofen, n (%) | 2 (3.45) | 2 (6.9) | 0 (0) | 0.49 |
Prednisone, n (%) | 0 (0) | 0 (0) | 0 (0) | - |
Tobramycin, n (%) | 13 (22.41) | 2 (6.9) | 11 (37.9) | 0.01 |
Inhaled steroids, n (%) | 37 (63.79) | 15 (51.7) | 22 (75.9) | 0.10 |
Diabetes, n (%) | 22 (37.93) | 10 (34.5) | 12 (41.4) | 0.79 |
Hospitalization, n (%) | 21 (36.2) | 6 (20.7) | 15 (51.7) | 0.03 |
Pseudomonas, n (%) | 42 (72.41) | 15 (51.7) | 27 (93.1) | < 0.01 |
Systemic Inflammation and Lung Function
Unadjusted | Adjusted* | Standardized Beta-Coefficient (per 1 SD increase in the levels of biomarker) | |||
---|---|---|---|---|---|
Biomarker | β ± SE |
P-value | β ± SE |
P-value | |
CRP, mg/L | -10.61 ± 2.65 | < 0.01 | -7.04 ± 1.98 | < 0.01 | -0.3134 |
IL-6, pg/mL | -10.72 ± 3.11 | < 0.01 | -5.53 ± 2.66 | 0.04 | -0.2159 |
IL-1β, pg/mL | -6.97 ± 3.36 | 0.04 | -4.65 ± 2.67 | < 0.01 | -0.1784 |
SP-D, μg/mL | -17.70 ± 7.95 | 0.03 | -9.83 ± 5.93 | 0.10 | -0.1584 |
CCL18, pg/mL | -6.33 ± 5.93 | 0.29 | -3.01 ± 4.23 | 0.48 | -0.0672 |
GzmB, pg/mL | 4.09 ± 2.27 | 0.08 | -0.33 ± 1.89 | 0.86 | -0.0187 |
LPS, pg/mL | 1.07 ± 7.44 | 0.89 | 13.30 ± 5.41 | 0.02 | 0.0239 |
sCD14, μg/mL | 1.88 ± 9.67 | 0.85 | -10.26 ± 6.96 | 0.15 | -0.1414 |
LBP, μg/mL | -22.28 ± 6.63 | < 0.01 | -16.02 ± 4.74 | < 0.01 | -0.2946 |
Circulating Systemic Inflammatory Biomarkers and Hospitalization History
Biomarker | Total (n = 58)* | Previously hospitalized (n = 21)* | Not previously hospitalized (n = 37)* |
P-value | Adjusted P-value†
| c-statistics |
---|---|---|---|---|---|---|
CRP, μg/mL | 3.0 (1.5, 6.1) | 3.5 (2.0, 8.0) | 2.8 (1.3, 5.6) | 0.50 | 0.51 | 0.795 |
IL-6, pg/mL | 2.2 (1.1, 4.2) | 3.6 (2.8, 5.8) | 1.7 (1.0, 3.1) | < 0.01 | 0.07 | 0.837 |
IL-1β, pg/mL | 0.16 (0.06, 0.29) | 0.19 (0.06, 0.50) | 0.10 (0.06, 0.20) | < 0.01 | 0.06 | 0.828 |
SP-D, ng/mL | 84.3 (64.0, 112.3) | 87.5 (75.3, 106.1) | 82.6 (63.7, 113.2) | 0.60 | 0.26 | 0.804 |
CCL18, ng/mL | 59.5 (41.4, 75.3) | 60.1 (38.7, 73.5) | 59.2 (44.5, 75.9) | 0.92 | 0.92 | 0.797 |
GzmB, pg/ml | 109.2 (25.5, 389.8) | 90.7 (25.4, 384.9) | 121.2 (26.2, 389.8) | 0.46 | 0.83 | 0.792 |
LPS, ng/mL | 1.1 (0.9, 1.3) | 1.3 (1.0, 1.4) | 1.0 (0.8, 1.3) | 0.01 | 0.04 | 0.841 |
sCD14, μg/mL | 1.1 (0.9, 1.3) | 1.1 (1.0, 1.3) | 1.1 (0.8, 1.3) | 0.89 | 0.49 | 0.789 |
LBP, μg/mL | 27.6 (22.0, 39.9) | 30.8 (23.7, 41.2) | 25.9 (18.8, 35.7) | 0.17 | 0.79 | 0.781 |